1. Scrip
  2. >>R&D
  3. >>Clinical Trials

AbbVie Logs Another Phase III Success With Tavapadon In Parkinson’s

 
• By Joseph Haas

The firm said it will file the D1/D5 dopamine receptor agonist for US FDA approval in 2025. The drug may salvage value from AbbVie’s Cerevel buyout.

AbbVie has a third successful Phase III trial for tavapadon (Shutterstock)

Whereas the primary driver of AbbVie’s $8.7bn acquisition of Cerevel, the schizophrenia candidate emraclidine, has been a disappointment, the pharma racked up a third positive Phase III readout for the first-in-class Parkinson’s disease candidate tavapadon on 9 December. Now, AbbVie says it intends to file tavapadon for US Food and Drug Administration approval in 2025.

Key Takeaways
  • AbbVie found success in a third Phase III trial of Parkinson’s disease candidate tavapadon and is planning an FDA filing in 2025.

In the 304-patient, flexible-dose TEMPO-2 study of tavapadon monotherapy – a first- and only-in-class partial agonist of the D1/D5 dopamine...

More from Clinical Trials

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

More from Therapy Areas

Scholar Rock Shows Muscle-Building PoC In Obesity

 
• By Jessica Merrill

The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.